TCGA-A8-A07Z-01A-11R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 46
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.490
- ESTROGEN_RESPONSE_EARLY+0.440
- ESTROGEN_RESPONSE_LATE+0.390
- CHOLESTEROL_HOMEOSTASIS+0.360
- OXIDATIVE_PHOSPHORYLATION+0.360
- APICAL_SURFACE+0.290
- INTERFERON_GAMMA_RESPONSE+0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.250
- FATTY_ACID_METABOLISM+0.240
- ADIPOGENESIS+0.230
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- UV_RESPONSE_DN-0.260
- KRAS_SIGNALING_UP-0.230
- TNFA_SIGNALING_VIA_NFKB-0.200
- INFLAMMATORY_RESPONSE-0.170
- HYPOXIA-0.140
- TGF_BETA_SIGNALING-0.140
- HEDGEHOG_SIGNALING-0.130
- WNT_BETA_CATENIN_SIGNALING-0.110
- PROTEIN_SECRETION-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG565 | — | — | 0.757 |
| 2 | TCGA-39-5024-01A-21R-1820-07 | — | cohortSQ1 | 0.699 |
| 3 | TCGA-BH-A6R8-01A-21R-A33J-07 | — | B | 0.695 |
| 4 | TCGA-A8-A09E-01A-11R-A00Z-07 | — | B | 0.694 |
| 5 | SRR1313114 | — | B | 0.694 |
| 6 | MNG1088 | — | — | 0.687 |
| 7 | TCGA-BH-A0DH-01A-11R-A084-07 | — | B | 0.678 |
| 8 | 47661ed9-5c0e-442d-b072-3da8b14fab02 | — | — | 0.667 |
| 9 | 7a458b19-1b7c-422c-b900-cd77e5009421 | — | — | 0.658 |
| 10 | ERR2208962 | — | — | 0.657 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.440 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.390 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.360 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.250 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.220 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.170 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.160 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |